.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
The STREAM trial compared a shorter, standardized regimen for rifampicin-resistant tuberculosis with the conventional longer treatment strategy. The randomized phase 3 study showed that a nine-to-eleven-month regimen could achieve favorable outcomes while substantially reducing the duration of treatment compared with the older 20-month approach. The trial is important because treatment duration is closely linked to adherence, toxicity, cost, and the practical burden placed on patients and health systems. For clinicians working in high TB-burden settings, the study illustrates why regimen design cannot be separated from implementation. Shorter therapy can make treatment more feasible, but careful patient selection, drug-resistance testing, toxicity monitoring, and adherence support remain essential. The paper also helps frame the conference discussion on drug-resistant TB: modern care is not only about choosing the right drug combination but also about delivering a regimen that patients can realistically complete. Its relevance extends to programmatic care because the gains from shorter treatment can be lost if diagnosis, follow-up, or access to medicines remains fragmented.
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
The STREAM trial compared a shorter, standardized regimen for rifampicin-resistant tuberculosis with the conventional longer treatment strategy. The randomized phase 3 study showed that a nine-to-eleven-month regimen could achieve favorable outcomes while substantially reducing the duration of treatment compared with the older 20-month approach. The trial is important because treatment duration is closely linked to adherence, toxicity, cost, and the practical burden placed on patients and health systems. For clinicians working in high TB-burden settings, the study illustrates why regimen design cannot be separated from implementation. Shorter therapy can make treatment more feasible, but careful patient selection, drug-resistance testing, toxicity monitoring, and adherence support remain essential. The paper also helps frame the conference discussion on drug-resistant TB: modern care is not only about choosing the right drug combination but also about delivering a regimen that patients can realistically complete. Its relevance extends to programmatic care because the gains from shorter treatment can be lost if diagnosis, follow-up, or access to medicines remains fragmented.
Today
The phase 3 ACACIA-HCM trial reveals that aficamten improves cardiac structure, diastolic relaxation, functional capacity, and symptom burden in symptomatic nonobstructive hypertrophic cardiomyopathy, marking a major milestone in targeted myosin inhibition.
6 days back
A clinical study shows that automated breast ultrasound paired with artificial intelligence accurately classifies BIRADS 3-4 lesions, reaching 95% sensitivity and 79% specificity. This diagnostic advance promises to reduce unnecessary core needle biopsies and refine clinical workflows in breast imaging.
3 weeks back
Researchers have engineered freestanding hierarchical-porous BCZT thin films that resist cracking and enhance ultrasonic energy harvesting in soft tissue. Achieving high piezoelectric output and acoustic matching, this lead-free material offers transformative potential for implantable bioelectronics.
6 days back
A novel pathology-adaptive surface engineering strategy uses functionalized plasma polymer coatings to selectively modulate AGE adsorption, reducing oxidative stress and restoring bone formation in diabetic and aging microenvironments.
3 weeks back
A breakthrough study identifies the Klotho/PKCα/CUX1/SPARC/TGFβ-RII axis as a critical driver of podocyte mitochondrial injury and ferroptosis in diabetic kidney disease, unveiling promising molecular targets to halt renal disease progression.
6 days back
